Popular bronchial scopes slapped with Class I recall

More than 17,000 medical devices used to diagnose and treat the lungs and airways are being recalled.

The FDA says the bronchoscopy devices—broncho-fiberscopes and broncho-videoscopes—have caused four burn-based injuries and drawn almost 200 complaints for sparking or catching fire.

No deaths have been reported, but the agency is labeling the action a Class I recall, the most stern type.

The manufacturer, Olympus, alerted customers who own the scopes to the presence of the risk in October, FDA says.

The recall applies to 17,691 scopes distributed between Jan. 1, 2001, and Sept. 11, 2023.

Olympus pointed users to the warning section in the operator’s manual, highlighting steps to avoid adverse events. These include “stop performing high-frequency cauterization while supplying oxygen” and “keep electrosurgical devices used with the endoscope far enough away from the endoscope.”

FDA notice here.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.